AtriCure logo
AtriCure
ATRC | NASDAQ
Chart Builder DCF Calculator
$55.31
-$1.53 (-2.69%)
At close: Nov 16, 2026, 4:00 PM ET
$55.31
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

AtriCure Company Profile

Company profile explained

Company Profile

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.

Key Executives

Name Position
Michael H. Carrel Chief Executive Officer, President & Director
Angela L. Wirick Chief Financial Officer
Douglas J. Seith Chief Operating Officer
Karl S. Dahlquist CCEP Chief Legal Officer
Justin J. Noznesky Chief Marketing & Strategy Officer
Salvatore Privitera Chief Technical Officer
Valerie Storch-Willhaus Vice President of Corporate Marketing & Communications
Vinayak Doraiswamy Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 05, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 24, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 10, 2026 4 Filing
Sep 04, 2026 4 Filing
Aug 26, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 07, 2026 4 Filing
Aug 07, 2026 4 Filing
View All SEC Filings ➞
AtriCure
AtriCure logo
Country United States
IPO Date Aug 5, 2005
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 1,350
CEO Michael H. Carrel

Contact Details

7555 Innovation Way Mason, Ohio 45040 United States

Stock Details

Ticker Symbol ATRC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001323885
CUSIP Number 04963C209
ISIN Number US04963C2098
SIC Code 3841

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.